Ionizing radiation can be used to induce the expression of cell surface molecules unique to cancer. Phage displayed peptide libraries can be used to discover peptides that bind specifically to irradiated cancers. Here, we show that the amino acid sequence HVGGSSV achieved tumor-specific binding when conjugated to nanoparticles containing radiationsensitizing paclitaxel. Radiation-guided delivery of nanoparticles improved both bioavailability of drug delivery and efficacy of radiotherapy in mouse models of lung cancer. Further studies are necessary to determine whether improved cancer-specific delivery of radiation-sensitizing chemotherapy translates to reduced side effects and better treatment outcomes in lung cancer patients.
Introduction
Drug delivery systems have been developed to increase drug delivery to cancer and thereby enhance therapeutic response (1-3). Examples of drug delivery systems include liposomal doxorubicin and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) (4), which are not ligand-targeted systems and therefore not tumor-specific (5-7). Nab-paclitaxel has features that make it an appropriate vehicle for drug encapsulation (8) (9) (10) . It is a natural carrier of hydrophobic molecules such as paclitaxel, and has non-covalent binding characteristics (11).
This allows paclitaxel to bind reversibly to albumin. Nab-paclitaxel binds to the albumin receptor, gp60, which is ubiquitously present throughout tissues (12) (13) (14) , and therefore does not reduce the incidence of complications (15) (16) (17) .
Physical energy has been used to achieve site-specific drug delivery to cancer. For example, heat is used to release drugs from liposomes and nanocages. These technologies are complemented by use of radiation-guided peptides conjugated to nab-paclitaxel. Ligands that can specifically target receptors within tumor microvasculature have been previously investigated (18, 3) . Radiation can be used to achieve site-specific expression of receptors within cancer (19, 20) . These radiation-inducible receptors can in turn be targeted by peptides selected through phage display technology (22) . Nanoparticle carriers can be functionalized with these peptide ligands to enable radiation-guided delivery of chemotherapeutic drugs to tumor microvasculature (19) (20) (21) (22) (23) (24) . This tumor-specific delivery of chemotherapy has the potential to improve treatment tolerability by reducing non-specific delivery of cytotoxic drugs to normal tissues and improve bioavailability of chemotherapy to cancer.
We studied nab-paclitaxel as a scaffold for creating a radiation-guided drug delivery system.
To increase tumor-specific delivery of paclitaxel and enhance tumor bioavailability, we functionalized nab-paclitaxel with a radiation-guided peptide (HVGGSSV) that specifically targets microvasculature within irradiated tumors. In this study, we focused on non-small cell Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Copyright © 2010 American Association for Cancer Research for near-infrared fluorescence imaging. For conjugation, 1 mg Alexa fluor 750 was dissolved in 100 ul of dimethyl sulfoxide (Sigma, St. Louis, MO) and added to HVGGSSV modified nabpaclitaxel for 1 hr in a phosphate buffered saline buffer at a pH of 7.
Animal Models. Animal studies were performed according to a protocol approved by
Vanderbilt's IACUC. Male athymic nude mice (nu/nu) between four to six weeks old (Harlan Inc., Indianapolis IN, USA) or C57BL6 male mice were anesthetized using a ketamine and xylazine solution before being injected subcutaneously in the hind legs with 1 x 10 6 LLC or H460 cells suspended in 100 μL sterile phosphate buffered saline. One week after inoculation, the tumors reached an approximate size of 0.5-0.8 cm in diameter, and the mice were used for studies.
Radiation and treatment protocol. Tumors were allowed to reach 0.5-0.8 cm 3 in size before beginning treatments. All mice were anesthetized using ketamine and xylazine solution prior to irradiation to inhibit mobility during treatment. Tumors were irradiated with 300kV X-rays using a Pantak Therapax 3 linear accelerator system (Pantak, East Haven, CT) with an adjustable collimator set to limit dosage to the tumor region only. During irradiation procedures, 1 cm thick lead blocks were arranged above the rest of the body, leaving only the desired area on the hind limb exposed for treatment. Four hours following radiation, mice were administered drug treatments through tail vein injection.
Imaging and image analysis. In vivo NIR imaging was performed with a Xenogen IVIS 200 small animal imaging system (Xenogen Inc., Alameda CA, USA) with a Cy7 filter set (excitation at 680 nm and emission at 775 nm). Nude mice bearing LLC or H460 lung carcinoma tumors implanted in both hind limbs were treated with radiation. The tumor on the left side of each mouse received a radiation dose of 3 Gy and the tumor on the right side received no radiation (sham radiation dose of 0 Gy) and served as an internal negative control.
Four hours following irradiation, mice were anesthetized using an intraperitoneal injection of with an internal standard of docetaxel, followed by solid-phase extraction with acetonitrile, and centrifuged at 3000 rpm (25) . Supernatant was removed and analyzed for paclitaxel content using HPLC-MS/MS. Results are presented as mean and SEM for a group of 3 animals.
Subcutaneous tumor models. 6-8 week old male athymic nude mice or C57BL6 mice were injected heterotopically with either 1x10 Gy), SGVSGHV-nab-paclitaxel with radiation (3Gy x 3). Radiation treatment was administered every other day (28 
Targeting nab-paclitaxel to irradiated cancer improves biodistribution.
To determine whether HVGGSSV-nab-paclitaxel binds within tumor microvasculature, we labeled HVGGSSV-nab-paclitaxel, SGVSGHV-nab-paclitaxel and nab-paclitaxel with fluorescent probe Alexa fluor 594 prior to injection. Approximately 3 hrs after treatment, mice were sacrificed, and tumors were excised and cryopreserved for fluorescence microscopy. 
Targeted nab-paclitaxel enhances therapeutic efficacy.
Therapeutic efficacy of HVGGSSV guided nab-paclitaxel was studied in two tumor models, murine Lewis lung carcinoma and NCI-H460 human large cell lung carcinoma grafted subcutaneously in C57 and athymic nude mice, respectively. On day 7 after tumor cell implantation, mice were injected with 10 mg/kg i.v. of either HVGGSSV-nab-paclitaxel, SGVSGHV-nab-paclitaxel, nab-paclitaxel, or saline. Tumor volumes for each treatment group were measured manually with calipers until they reached a 4-fold increase in volume. Figure   5A and B show radiation alone (9 Gy) achieved only a slight tumor growth delay (2 days) in LLC tumors, and 6 days in H460 tumors as compared to untreated controls. Negative SGVSGHV-nab-paclitaxel controls showed no significant growth delay in LLC tumors and only 2 days delay in H460. After subsequent irradiation, this was improved to 2 days (LLC) and 6 days (H460). Treatment with nab-paclitaxel alone produced tumor growth delay of 2 days (LLC) and 6 days (H460), and upon additional irradiation increased to 6 days (LLC) and 11
Research. 
Discussion
Cancer-selective therapy using various targeted strategies include antibodies, peptides, aptamers, and other targeting moieties that bind to receptors or antigens that are specific to cancer (1, 3, 6, 7, (36) (37) (38) (39) . Radiation can be used to induce the expression of receptors within tumor microvasculature (19) (20) (21) (22) . Tumor targeting peptides were developed to bind to these radiation-inducible receptors. These peptides can then be modified with nanoparticles containing cytotoxic drugs to create radiation-guided drug delivery systems. Previously, the GIRLRG peptide has been used to target the GRP78 receptors in breast and brain tumors, but not lung cancer models (21) . In that study, the GRP78 ligand was conjugated to a non-GMP These peptide ligands can be used to functionalize nanoparticle carriers for radiation-guided delivery of chemotherapeutic drugs to tumor microvasculature (19) (20) (21) (22) 24) . This strategy has the potential to increase the therapeutic ratio by delivering chemotherapy specifically to tumors and reducing toxic side effects from non-specific delivery commonly produced by systemic chemotherapy. In this study, we found that the chemotherapeutic drug nab-paclitaxel can be targeted specifically to tumors using the radiation-guided peptide HVGGSSV. 
